Vivoryon Therapeutics N.V. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported net loss was EUR 10.72 million compared to EUR 12.58 million a year ago. Basic loss per share from continuing operations was EUR 0.44 compared to EUR 0.6 a year ago.